Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of MoonLake Immunotherapeutics with an Overweight rating and $23 price target. The analyst says the opportunity for sonelokimab in hidradenitis suppurativa is the primary driver of Cantor’s bullish view. The firm has "high confidence" that sonelokimab will work in HS and likely "raise the efficacy bar due to its optimal inhibition profile and a nanobody approach."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MLTX:
- MoonLake completes patient enrollment in Phase 2 trial of Nanobody sonelokimab
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
- MoonLake Immunotherapeutics initiated with a Buy at Bryan Garnier